The sum of life years (LY) of the women with HER2+ early BC during the analytical period for all the cohorts was 605,358 years in the trastuzumab + chemotherapy (T+CT) scenario, versus 564,137 in the hypothetical scenario of the absence of trastuzumab as adjuvant therapy (CT) since 2006. The gene discussed is ERBB2; the disease is breast cancer.